Search Result

Results for "

influenza endonuclease,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Influenza Virus (36) Isotope-Labeled Compounds (2) Reference Standards (2)
By Research Areas:	Cancer (3) Infection (34) Inflammation/Immunology (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Endonuclease Influenza Virus

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164927

AV5124	Influenza Virus	Infection Inflammation/Immunology
AV5124, a prodrug of AV5116, is an orally active **influenza virus cap-dependent endonuclease (CEN) endonuclease** inhibitor .

HY-144066

Cap-dependent endonuclease-IN-21	Influenza Virus	Infection
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .

HY-144067

Cap-dependent endonuclease-IN-23	Influenza Virus	Infection
Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .

HY-143752

Cap-dependent endonuclease-IN-8	Influenza Virus	Infection
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .

HY-143750

Cap-dependent endonuclease-IN-7	Influenza Virus	Infection
Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)

HY-143757

Cap-dependent endonuclease-IN-10	Influenza Virus	Infection
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .

HY-143768

Cap-dependent endonuclease-IN-14	Influenza Virus	Infection
Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .

HY-143766

Cap-dependent endonuclease-IN-13	Influenza Virus	Infection
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .

HY-143744

Cap-dependent endonuclease-IN-3	Influenza Virus	Infection
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .

HY-173204

Influenza virus-IN-9	Influenza Virus	Infection Inflammation/Immunology
Influenza virus-IN-9 (12) is an **influenza endonuclease** inhibitor, with an IC₅₀ of 0.03 μM .

HY-N10581

Flutimide	Influenza Virus	Infection
Flutimide is a novel *endonuclease* inhibitor of influenza virus. Flutimide selectively inhibits endonuclease with an IC₅₀ value of 3 μM. Flutimide shows antiviral activity in cell culture. Flutimide can be used for the research of acute contagious respiratory disease, such as influenza .

HY-174431

PAN endonuclease-IN-3	Influenza Virus	Infection
PAN endonuclease-IN-3 is a potent PAN endonuclease inhibitor that against influenza virus polymerase complexes with an IC₅₀ of 17.4 nM. PAN endonuclease-IN-3 demonstrates potent inhibitory activities against PAN endonuclease. PAN endonuclease-IN-3 demonstrates robust antiviral activities against multiple current and different influenza virus strains while showing minimal cytotoxicity in MDCK cells. PAN endonuclease-IN-3 significantly suppresses viral replication in an A/WSN/33 infected mouse model.

HY-143781

Cap-dependent endonuclease-IN-26	Influenza Virus	Infection
Cap-dependent endonuclease-IN-26 is a *cap-dependent endonuclease* (CEN) inhibitor with an IC₅₀** of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .

HY-143749

Cap-dependent endonuclease-IN-6	Influenza Virus	Infection
Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC₅₀=38.21 nM) .

HY-143769

Sebaloxavir marboxil Cap-dependent endonuclease-IN-15	Influenza Virus	Infection
Sebaloxavir marboxil (Cap-dependent endonuclease-IN-15) (Compound c-1) is a potent inhibitor of cap-dependent endonuclease (CEN). Sebaloxavir marboxil inhibits the replication of influenza virus. Sebaloxavir marboxil has the potential for the research of viral infections caused by influenza viruses .

HY-143770

Cap-dependent endonuclease-IN-16	Influenza Virus	Infection
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .

HY-153570

Influenza virus-IN-7	Influenza Virus	Infection
Influenza virus-IN-7 (Example 16) is an orally active cap-dependent endonuclease inhibitor that can be used for the research of influenza viral infectious diseases .

HY-112684

RO-7	Influenza Virus	Infection
RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.

HY-109025

Baloxavir marboxil 5+ Cited Publications S-033188; RG 6152	Influenza Virus	Infection Cancer
Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent *endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza* A and B virus .

HY-152078

Influenza virus-IN-6	Influenza Virus	Infection
Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PA_N) endonuclease inhibitor with an IC₅₀ of 0.20 μM .

HY-163147

PAN endonuclease-IN-1	Influenza Virus	Infection
PAN endonuclease-IN-1 (Compound 23) is a potent PAN endonuclease inhibitor, with K_d values of 277 μM, 384 μM and 328 μM for WT, I38T and E23K PA_N endonucleases, respectively. The RNA-dependent RNA polymerase acidic N-terminal (PAN) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target .

HY-158028

PAN endonuclease-IN-2	Influenza Virus	Infection
PAN endonuclease-IN-2 (compound T-31) is a PA_N endonuclease inhibitor (IC₅₀: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .

HY-143775

Cap-dependent endonuclease-IN-20	Influenza Virus	Infection
Cap-dependent endonuclease-IN-20 is a *cap-dependent endonuclease* (CEN)** inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 4.82 μM (CN112940009A; DSC801) .

HY-143771

Cap-dependent endonuclease-IN-17	Influenza Virus	Infection
Cap-dependent endonuclease-IN-17 is a *cap-dependent endonuclease* (CEN)** inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 1.29 μM (CN112898346A; DSC701) .

HY-143492

Influenza virus-IN-1	Influenza Virus	Inflammation/Immunology
Influenza virus-IN-1 (compound 14) is a potent influenza A virus inhibitor with an EC₅₀ of 2.46 µM and CC₅₀ of >200 µM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PA_N endonuclease with EC₅₀ of 312.36 nM. Influenza virus-IN-1 shows shows anti-influenza A virus activities .

HY-143747

Cap-dependent endonuclease-IN-5	Influenza Virus	Infection
Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .

HY-143493

Influenza virus-IN-2	Influenza Virus	Inflammation/Immunology
Influenza virus-IN-2 (compound 19) is a potent influenza virus inhibitor with an EC₅₀ of 2.58 µM and CC₅₀ of 150.85 µM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PA_N endonuclease with EC₅₀ of 489.39 nM. Influenza virus-IN-2 shows shows anti-influenza A virus activities .

HY-162242

Cap-dependent endonuclease-IN-27	Influenza Virus	Infection
Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC₅₀ = 12.26 nM) .

HY-132894

Pixavir marboxilo	Influenza Virus	Infection
Pixavir marboxilo is an orally active cap-dependent endonuclease inhibitor with high potency. Pixavir marboxilo can be used for the research of influenza .

HY-143755

Cap-dependent endonuclease-IN-9	Influenza Virus	Infection
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .

HY-143743

Cap-dependent endonuclease-IN-2	Influenza Virus	Infection
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .

HY-118368

L-742001 hydrochloride	Influenza Virus	Infection Inflammation/Immunology
L-742001 hydrochloride is an **influenza virus PA endonuclease** inhibitor, with an EC₉₀ of 4.3 μM for vRNP activity in HEK293T cells .

HY-109025R

Baloxavir marboxil (Standard) S-033188 (Standard); RG 6152 (Standard)	Reference Standards Influenza Virus	Infection
Baloxavir marboxil (Standard) is the analytical standard of Baloxavir marboxil. This product is intended for research and analytical applications. Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent *endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza* A and B virus .

HY-109025A

Baloxavir 35+ Cited Publications Baloxavir acid; S-033447	Influenza Virus	Infection Cancer
Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective *cap-dependent endonuclease* (CEN)** inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025AS

Baloxavir-d5 Baloxavir acid-d₅; S-033447-d₅	Isotope-Labeled Compounds Influenza Virus	Infection
Baloxavir-d₅ is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025AR

Baloxavir (Standard) Baloxavir acid (Standard); S-033447 (Standard)	Reference Standards Influenza Virus	Infection
Baloxavir (Standard) is the analytical standard of Baloxavir. This product is intended for research and analytical applications. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective *cap-dependent endonuclease* (CEN)** inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-W751835

Baloxavir-d4 Baloxavir acid-d₄; S-033447-d₄	Isotope-Labeled Compounds	Others Cancer
Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective *cap-dependent endonuclease* (CEN)** inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10581

Flutimide	Microorganisms	Influenza Virus
Flutimide is a novel *endonuclease* inhibitor of influenza virus. Flutimide selectively inhibits endonuclease with an IC₅₀ value of 3 μM. Flutimide shows antiviral activity in cell culture. Flutimide can be used for the research of acute contagious respiratory disease, such as influenza .

Cat. No.	Product Name	Chemical Structure

HY-W751835

Baloxavir-d4
Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective *cap-dependent endonuclease* (CEN)** inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

Baloxavir-d4

Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025AS

Baloxavir-d5
Baloxavir-d₅ is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks